<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05061238</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0620</org_study_id>
    <nct_id>NCT05061238</nct_id>
  </id_info>
  <brief_title>Impact Of Muscle Vibration On Gait Control</brief_title>
  <official_title>Impact Of Muscle Vibration On Gait Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-site interventional open label pilot study of a non-significant risk medical&#xD;
      device on patients with defined peripheral neuropathy secondary to chemotherapy (N=10).&#xD;
      Patients who have received chemotherapy and have evidence of neuropathy will be seen at MD&#xD;
      Anderson. Their severity of neuropathy will be documented and assessed by physical therapy,&#xD;
      occupational therapy and based on self-reported activities of daily living (ADL) impairment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To assess the effect of a vibrating device applied to selected muscles on the step&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To summarize the adverse events of different levels from using the vibrator device in&#xD;
           oncologic AYA patients visiting the outpatient clinic.&#xD;
&#xD;
        -  To summarize the irritation, pain, and sensation of the application of vibration by the&#xD;
           AYA patients, as determined by the survey during the application&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the effect of a vibrating device applied to selected muscles on the step times of adolescent or young adult (AYA).</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Muscle</condition>
  <arm_group>
    <arm_group_label>Vibrating Device</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>you will be asked to walk up and down a hallway 5 times with the vibrating device strapped to different parts of your leg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vibrating Device</intervention_name>
    <description>The vibrating device strapped to different parts of your leg. The device will be secured to your leg with a Velcro strap.</description>
    <arm_group_label>Vibrating Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects between the ages of 15 and 39 years.&#xD;
&#xD;
          -  Study subjects, or their parent/legal guardian for subjects &lt;18 years, must be able to&#xD;
             understand the purpose and risks of the study and to provide signed and dated informed&#xD;
             consent and authorization to use confidential health information in accordance with&#xD;
             national and local subject privacy regulations.&#xD;
&#xD;
          -  History of any type of cancer&#xD;
&#xD;
          -  Diagnosed with peripheral neuropathy-associated gait dysfunction as defined by the&#xD;
             treating physician.&#xD;
&#xD;
          -  Able (in the Investigators estimation) and willing to comply with all study&#xD;
             requirements.&#xD;
&#xD;
          -  Subjects must be able to walk without the assistance of a walker or similar support&#xD;
             apparatus.&#xD;
&#xD;
          -  Patients with ankle foot orthosis (AFOs) are allowed but will need to be removed prior&#xD;
             to testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with amputations, prosthetics, congenital malformations or any severe&#xD;
             lower extremity deformities affecting gait before trials.&#xD;
&#xD;
          -  Abnormalities of the lower extremities as determined by the investigator.&#xD;
&#xD;
          -  Unstable participants or participants with hypotension (systolic blood pressure &lt;90&#xD;
             and diastolic blood pressure &lt; 60mmHg).&#xD;
&#xD;
          -  Any other significant disease or disorder which, in the opinion of the investigator,&#xD;
             may either put the participants at risk because of participation in the study, or may&#xD;
             influence the result of the study, or the participant's ability to participate in the&#xD;
             study.&#xD;
&#xD;
          -  Other unspecified reasons that, in the opinion of the Investigator make the subject&#xD;
             unsuitable for enrolment&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Children &lt;15 years old&#xD;
&#xD;
          -  Blind&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David McCall</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David McCall</last_name>
    <phone>713) 792-6604</phone>
    <email>dmccall1@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David McCall</last_name>
      <phone>713-792-6604</phone>
      <email>dmccall1@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

